Tamoxifen therapy for breast cancer and endometrial cancer risk

被引:248
|
作者
Bernstein, L
Deapen, D
Cerhan, JR
Schwartz, SM
Liff, J
McGann-Maloney, E
Perlman, JA
Ford, L
机构
[1] Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Dept Prevent Med, Los Angeles, CA 90033 USA
[2] Univ So Calif, Sch Med, Dept Prevent Med, Los Angeles, CA 90033 USA
[3] Mayo Clin, Dept Hlth Sci Res, Rochester, MN USA
[4] Univ Washington, Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98195 USA
[5] Univ Washington, Sch Publ Hlth & Community Med, Dept Epidemiol, Seattle, WA 98195 USA
[6] Emory Univ, Rollins Sch Publ Hlth, Dept Epidemiol, Atlanta, GA USA
[7] US Publ Hlth Serv, Washington, DC USA
[8] Epimedix, Washington, DC USA
[9] NCI, Div Canc Prevent, Bethesda, MD USA
关键词
D O I
10.1093/jnci/91.19.1654
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Tamoxifen is effective in treating breast cancer, reduces breast cancer incidence among high-risk women, and is associated with increased endometrial cancer risk, This study was designed to examine the possible modifying effects of endometrial cancer risk factors on the tamoxifen-endometrial cancer association. Methods: We conducted a case-control study of endometrial cancer (324 case patients and 671 individually matched control subjects) nested within a population-based cohort of patients with breast cancer diagnosed from 1978 through 1992 within four regions of the United States. We obtained information on breast cancer treatment and endometrial cancer risk factors through interviews and reviews of medical records. All P values reported are two-sided. Results: Endometrial cancer risk was associated with tamoxifen therapy for breast cancer (odds ratio = 1.52; 95% confidence interval [CI] = 1.07-2.17). Risk increased with duration of tamoxifen use (P for trend =.0002), Women with more than 5 years of exposure to tamoxifen had 4.06-fold greater odds of developing endometrial cancer than nonusers (95% CI = 1.74-9.47). Prior use of estrogen replacement therapy (ERT) increased risk associated with tamoxifen use (P for homogeneity of trends <.0001), Risk associated with tamoxifen use was stronger among heavier women than among thinner women, although trends did not differ statistically (P =.10). Tamoxifen dose-response effects were more pronounced among women with both previous ERT exposure and higher body mass index than among women in other risk groups, Conclusions: ERT use and obesity, both established endometrial cancer risk factors and markers of estrogen exposure, substantially modify the association between tamoxifen use and endometrial cancer risk among patients with breast cancer. Women with positive ERT histories and those who are obese, when prescribed tamoxifen, may warrant closer surveillance for endometrial cancer than women without such histories.
引用
收藏
页码:1654 / 1662
页数:9
相关论文
共 50 条
  • [1] The combined effects of ERT, obesity and tamoxifen therapy for breast cancer on endometrial cancer risk
    Bernstein, L
    Cerhan, J
    Schwartz, S
    Liff, J
    Perlman, J
    Ford, L
    [J]. EUROPEAN JOURNAL OF CANCER, 1998, 34 : S46 - S46
  • [2] Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
    Bergman, L
    Beelen, MLR
    Gallee, MPW
    Hollema, H
    Benraadt, J
    van Leeuwen, FE
    [J]. LANCET, 2000, 356 (9233): : 881 - 887
  • [3] Tamoxifen and the risk of endometrial cancer in Japanese women with breast cancer
    Yamazawa, K
    Miyazawa, Y
    Suzuki, M
    Wakabayashi, M
    Kaku, H
    Matsui, H
    Sekiya, S
    [J]. SURGERY TODAY, 2006, 36 (01) : 41 - 46
  • [4] Tamoxifen and the Risk of Endometrial Cancer in Japanese Women with Breast Cancer
    Koji Yamazawa
    Yukimasa Miyazawa
    Masato Suzuki
    Maki Wakabayashi
    Hiroshi Kaku
    Hideo Matsui
    Souei Sekiya
    [J]. Surgery Today, 2006, 36 : 41 - 46
  • [5] Risk and prognosis of endometrial cancer after tamoxifen for breast cancer
    Engel, J
    Hölzel, D
    [J]. STRAHLENTHERAPIE UND ONKOLOGIE, 2001, 177 (07) : 371 - 371
  • [6] Endometrial abnormalities in breast cancer patients with tamoxifen therapy
    Prevedourakis, C
    Makris, N
    Xygakis, A
    Dachlythras, M
    Michalas, S
    [J]. GYNAECOLOGICAL ENDOSCOPY, 2000, 9 (01) : 23 - 26
  • [7] RISK OF ENDOMETRIAL CANCER AFTER TAMOXIFEN TREATMENT OF BREAST-CANCER
    VANLEEUWEN, FE
    BENRAADT, J
    COEBERGH, JWW
    KIEMENEY, LALM
    GIMBRERE, CHF
    OTTER, R
    SCHOUTEN, LJ
    DAMHUIS, RAM
    BONTENBAL, M
    DIEPENHORST, FW
    VANDENBELTDUSEBOUT, AW
    VANTINTEREN, H
    [J]. LANCET, 1994, 343 (8895): : 448 - 452
  • [8] Tamoxifen therapy for primary breast cancer and risk of contralateral breast cancer
    Li, CI
    Malone, KE
    Weiss, NS
    Daling, JR
    [J]. JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2001, 93 (13) : 1008 - 1013
  • [9] Tamoxifen and risk of endometrial cancer
    Lasset, C
    Bonadona, V
    Mignotte, H
    Brémond, A
    [J]. LANCET, 2001, 357 (9249): : 66 - 67
  • [10] Stroke risk and tamoxifen therapy for breast cancer
    Geiger, AM
    Fischberg, GM
    Chen, WS
    Bernstein, L
    [J]. JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2004, 96 (20) : 1528 - 1536